1. Scrip
  2. >>New Products

56 Biosimilars In Late-Stage Development Line Up To Challenge Top Biologic Drugs

 
• By Ian Schofield

Many key biologic drugs, including adalimumab, bevacizumab, rituximab and trastuzumab, are facing biosimilar competition from products that have been either filed or recently approved in Europe, and 56 biosimilars are now at a late stage of clinical development, according to Per Troein of QuintilesIMS.

Tooth wheel mechanism with DIFFERENT, SIMILAR letters
Biosimilars are increasing their market share in Europe • Source: Shutterstock

56 biosimilar products are in late-stage development at global level, 47 of which are in Phase III trials and nine at the pre-registration stage. The top diseases being targeted are autoimmune disease (27 of the late-stage 56 products) and oncology (24), followed by diabetes (four), respiratory disease (two) and others (three). 68 biosimilars are at the preclinical stage, 14 are in Phase I trials and three are in Phase II.

The figures were presented by Per Troein, vice-president strategic partners at QuintilesIMS, during the recent Medicines for Europe annual biosimilars...

More from New Products

Gilead’s Yeztugo Gets US Approval For Twice-Yearly PrEP

 
• By Alexandra Shimmings

The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.

Pipeline Watch: Eight Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Nuvation Set For First Launch With Ibtrozi In Lung Cancer

 
• By Jessica Merrill

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

More from Scrip